Joanne M Fuller

Dr. Joanne M Fuller

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Patient Education and Counseling
Verified
Journal Article
Closed access
JFJoanne M Fuller
Joanne M Fuller
KWKeith K. Wong
Keith K. Wong
IKInes Krass
Ines Krass
RGRonald Grunstein
Ronald Grunstein
BSBandana Saini
Bandana Saini


22 May 2009 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
ATAdam Tran
Adam Tran
JFJoanne M Fuller
Joanne M Fuller
KWKeith K. Wong
Keith K. Wong
IKInes Krass
Ines Krass
RGRon Grunstein
Ron Grunstein
BSBandana Saini
Bandana Saini

29 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JFJoanne M Fuller
Joanne M Fuller
KWKeith K. Wong
Keith K. Wong
RGRonald Grunstein
Ronald Grunstein
IKInes Krass
Ines Krass
JPJayshree Patel
Jayshree Patel
BSBandana Saini
Bandana Saini
Community pharmacies may potentially assist in screening for chronic conditions such as sleep disorders, which remain both under-diagnosed and untreated. We aimed to compare a subjective risk-assessment-only questionnaire (RAO) for common sleep disorder screening against the same risk-assessment questionnaire plus a nasal flow monitor as an objective marker of possible underlying obstructive sleep apnea (OSA) (RA+) in a community pharmacy setting. The primary outcome was the number of participants identified in RAO or RA+ group who were likely to have and consequently be diagnosed with OSA. Further outcomes included the number of participants identified as being at risk for, referred for, taking-up referral for, and then diagnosed with OSA, insomnia, and/or restless legs syndrome (RLS) in either group. In a cluster-randomized trial, participants were recruited through 23 community pharmacies. Using validated instruments, 325 (RAO = 152, RA+ = 173) participants were screened for OSA, insomnia, and RLS. 218 (67%) participants were at risk of OSA, insomnia or RLS and these participants were referred to their primary physician. The proportion of screened participants identified as being at risk of OSA was significantly higher in the RA+ group (36% in RAO vs. 66% in RA+, OR 3.4, 95% CI (1.8–6.5), p<0.001). A 12-month follow-up was completed in 125 RAO and 155 RA+ participants. Actual referral uptake was 34% RAO, 26% RA+, OR 4.4, 95% CI (1.4–19.2), p = 0.31. The OSA diagnosis rate was higher in the RA+ arm (p = 0.01). To yield a single additional confirmed OSA diagnosis, 16 people would need to be screened using the RA+ protocol. These results demonstrate that utilising either screening method is feasible in identifying individuals in the community pharmacy setting who are likely to have OSA, insomnia and/or RLS. Secondly, adding an objective marker of OSA to a questionnaire-based prediction tool resulted in more confirmed OSA diagnoses. : ACTR.org.au ACTRN12608000628347

25 September 2021 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
HGHanna Gyllensten
Hanna Gyllensten
JFJoanne M Fuller
Joanne M Fuller
MÖMalin Johansson Östbring
Malin Johansson Östbring
Health systems in many countries are currently undergoing an evolution towards more person-centred care. However, an overview of the literature shows that there is little or no guidance available on how to apply person-centred care to pharmaceutical care and clinical pharmacy practices. In this paper we apply a model for person-centred care created by a national multidisciplinary research centre in Gothenburg, Sweden, to the clinical work tasks of outpatient and inpatient pharmacists and describe how pharmaceutical care can become more person-centred.

19 November 2009 in Cancer
Verified
Journal Article
Open access
PDF file
IHIsla M. Hains
Isla M. Hains
JFJoanne M Fuller
Joanne M Fuller
RWRobyn L. Ward
Robyn L. Ward
DPDr Sallie Pearson
Dr Sallie Pearson
BACKGROUND: Medical oncology is embracing information technology to standardize care and improve patient outcomes, with a range of Web‐based systems used internationally. The authors' aim was to determine the factors affecting the uptake and use of a Web‐based protocol system for medical oncology in the Australian setting.METHODS: The authors conducted 50 interviews and observed medical oncology physicians, nurses, and pharmacists in their treatment setting at 6 hospitals in different geographic locations.RESULTS: The Web‐based system plays a major role in guiding oncology treatment across participating sites. However, its use varies according to hospital location, clinician roles, and experience. A range of issues impact on clinicians' attitudes toward and use of the Web‐based system. Important factors are clinician‒specific (eg, their need for autonomy and perceptions of lack of time) or environmental (eg, hospital policy on protocol use, endorsement of the system, and the availability of appropriate infrastructure, such as sufficient computers). The level of education received regarding the system was also found to be integral to its ongoing use.CONCLUSIONS: Although the provision of high‐quality evidence‐based resources, electronic or otherwise, is essential for standardizing care and improving patient outcomes, the authors' findings demonstrate that this alone does not ensure uptake. It is important to understand end‐users, the environment in which they operate, and the basic infrastructure required to implement such a system. Implementation must also be accompanied by continuing education and endorsement to ensure both long‐term sustainability and use of the system to its full potential. Cancer 2009. © 2009 American Cancer Society.